Repligen Co. (NASDAQ:RGEN) Receives $173.25 Average Price Target from Brokerages

Repligen Co. (NASDAQ:RGEN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fourteen analysts that are covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $173.25.

A number of analysts have commented on RGEN shares. Canaccord Genuity Group decreased their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Royal Bank of Canada lowered their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Finally, Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th.

Repligen Stock Down 0.7%

NASDAQ RGEN traded down $0.87 on Wednesday, hitting $132.00. 479,647 shares of the company were exchanged, compared to its average volume of 746,912. The stock has a fifty day moving average of $127.51 and a 200-day moving average of $143.27. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The company has a market cap of $7.42 billion, a PE ratio of -258.82, a PEG ratio of 4.54 and a beta of 1.11. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same period in the prior year, the business earned $0.28 EPS. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Activity

In other news, Director Margaret Pax bought 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Repligen by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock worth $962,711,000 after purchasing an additional 430,039 shares during the period. Vanguard Group Inc. raised its position in Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after buying an additional 122,595 shares during the period. Alliancebernstein L.P. grew its position in shares of Repligen by 1.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock worth $130,317,000 after buying an additional 13,284 shares during the last quarter. Finally, Conestoga Capital Advisors LLC increased its stake in shares of Repligen by 3.4% during the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after buying an additional 32,665 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.